TYRA - Company ID 0001863127
The table below shows Tyra Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M | -$7.76M |
| Capital expenditure | $141.00K | $664.00K | $770.00K | $559.00K | $661.00K | $312.00K |
| Investing cash flow | $72.46M | -$98.40M | -$144.60M | -$559.00K | -$645.00K | -$312.00K |
| Dividends paid | - | - | - | - |
Tyra Biosciences, Inc. reported operating cash flow of -$95.14M for fiscal year 2025. That is down 36.4% from -$69.77M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.76M (FY 2020) to -$95.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $8.10M | $202.14M | $1.54M | $632.00K | $311.35M | $23.43M |